Jaguar Health, Inc. — Form 8-K Summary
Reporting date: September 25, 2026; filed and signed September 28, 2026. This current report describes a debt-for-equity exchange, not a quarterly or annual financial results period.
Transaction and key figures
- Jaguar issued Streeterville Capital, LLC 481,584 shares of common stock in exchange for a $3.4 million reduction in the outstanding balance of its 2021 secured promissory note.
- The note was originally issued in 2021 with principal of $6,220,812.50 and had been amended. The filing does not state its remaining balance after the exchange.
- Jaguar reported approximately 1,945,542 common shares issued and outstanding as of September 25, 2026.
- The shares were issued in an unregistered transaction under the Securities Act exemption in Section 3(a)(9).
Financial performance and outlook
The filing provides no revenue, profit, cash flow, margin, liquidity, or other operating results, and gives no guidance or outlook. It does not describe other contingencies or unusual items beyond the note exchange.
Investor items to verify
- The note’s remaining balance and other applicable terms after the $3.4 million reduction.
- The final exchange agreement and any related covenants or representations; the filing includes a form of the agreement as Exhibit 10.1.
- The resulting ownership and dilution impact, using the reported share count and the exchange shares issued.